T0	KEYPHRASE-NOTYPES 26 38	Lyme disease
T1	KEYPHRASE-NOTYPES 50 56	stages
T2	KEYPHRASE-NOTYPES 63 77	primary lesion
T3	KEYPHRASE-NOTYPES 98 103	stage
T4	KEYPHRASE-NOTYPES 118 122	site
T5	KEYPHRASE-NOTYPES 126 146	Borrelia inoculation
T6	KEYPHRASE-NOTYPES 152 161	infection
T7	KEYPHRASE-NOTYPES 177 193	erythema migrans
T8	KEYPHRASE-NOTYPES 205 212	redness
T9	KEYPHRASE-NOTYPES 218 237	erythematous papule
T10	KEYPHRASE-NOTYPES 270 274	days
T11	KEYPHRASE-NOTYPES 287 293	plaque
T12	KEYPHRASE-NOTYPES 311 327	central clearing
T13	KEYPHRASE-NOTYPES 329 332	Fig
T14	KEYPHRASE-NOTYPES 347 358	development
T15	KEYPHRASE-NOTYPES 362 364	EM
T16	KEYPHRASE-NOTYPES 370 377	patient
T17	KEYPHRASE-NOTYPES 392 415	constitutional symptoms
T18	KEYPHRASE-NOTYPES 424 429	fever
T19	KEYPHRASE-NOTYPES 431 438	malaise
T20	KEYPHRASE-NOTYPES 444 452	headache
T21	KEYPHRASE-NOTYPES 458 469	skin lesion
T22	KEYPHRASE-NOTYPES 489 493	pain
T23	KEYPHRASE-NOTYPES 497 505	pruritus
T24	KEYPHRASE-NOTYPES 511 535	regional lymphadenopathy
T25	KEYPHRASE-NOTYPES 560 578	untreated subjects
T26	KEYPHRASE-NOTYPES 585 596	early stage
T27	KEYPHRASE-NOTYPES 602 604	EM
T28	KEYPHRASE-NOTYPES 617 635	manifestation
T29	KEYPHRASE-NOTYPES 639 651	Lyme disease
T30	KEYPHRASE-NOTYPES 660 675	first weeks
T31	KEYPHRASE-NOTYPES 682 691	infection
T32	KEYPHRASE-NOTYPES 693 704	spirochetes
T33	KEYPHRASE-NOTYPES 726 731	blood
T34	KEYPHRASE-NOTYPES 748 765	American patients
T35	KEYPHRASE-NOTYPES 808 819	bloodstream
T36	KEYPHRASE-NOTYPES 823 836	tissues
T37	KEYPHRASE-NOTYPES 838 846	101-103 ]
T38	KEYPHRASE-NOTYPES 848 852	Note
T39	KEYPHRASE-NOTYPES 868 885	culture isolation
T40	KEYPHRASE-NOTYPES 891 896	blood
T41	KEYPHRASE-NOTYPES 933 950	European patients
T42	KEYPHRASE-NOTYPES 963 971	104-106 ]
T43	KEYPHRASE-NOTYPES 993 1005	routes
T44	KEYPHRASE-NOTYPES 1009 1022	dissemination
T45	KEYPHRASE-NOTYPES 1029 1046	secondary lesions
T46	KEYPHRASE-NOTYPES 1051 1069	Borrelia infection
T47	KEYPHRASE-NOTYPES 1075 1099	early disseminated stage
T48	KEYPHRASE-NOTYPES 1111 1130	multiple EM lesions
T49	KEYPHRASE-NOTYPES 1132 1163	widespread erythematous plaques
T50	KEYPHRASE-NOTYPES 1216 1230	initial lesion
T51	KEYPHRASE-NOTYPES 1236 1260	early disseminated stage
T52	KEYPHRASE-NOTYPES 1289 1310	Lyme neuroborreliosis
T53	KEYPHRASE-NOTYPES 1312 1315	LNB
T54	KEYPHRASE-NOTYPES 1322 1330	carditis
T55	KEYPHRASE-NOTYPES 1332 1349	European patients
T56	KEYPHRASE-NOTYPES 1369 1380	skin lesion
T57	KEYPHRASE-NOTYPES 1388 1410	borrelial lymphocytoma
T58	KEYPHRASE-NOTYPES 1423 1428	stage
T59	KEYPHRASE-NOTYPES 1430 1433	Fig
T60	KEYPHRASE-NOTYPES 1444 1464	tertiary skin lesion
T61	KEYPHRASE-NOTYPES 1474 1483	infection
T62	KEYPHRASE-NOTYPES 1500 1507	decades
T63	KEYPHRASE-NOTYPES 1519 1530	association
T64	KEYPHRASE-NOTYPES 1536 1547	Borreliawas
T65	KEYPHRASE-NOTYPES 1558 1592	acrodermatitis chronic atrophicans
T66	KEYPHRASE-NOTYPES 1596 1606	focal area
T67	KEYPHRASE-NOTYPES 1645 1654	extremity
T68	KEYPHRASE-NOTYPES 1656 1691	Acordermatitis chronica atrophicans
T69	KEYPHRASE-NOTYPES 1693 1696	ACA
T70	KEYPHRASE-NOTYPES 1720 1726	Europe
T71	KEYPHRASE-NOTYPES 1769 1792	late disseminated stage
T72	KEYPHRASE-NOTYPES 1817 1849	late neurological manifestations
T73	KEYPHRASE-NOTYPES 1860 1862	LA
T74	KEYPHRASE-NOTYPES 1884 1908	early disseminated stage
T75	KEYPHRASE-NOTYPES 1950 1973	late disseminated stage
